Mizuho has recently reduced Athira Pharma Inc (ATHA) stock to Neutral rating, as announced on September 19, 2024, according to Finviz. Earlier, on September 4, 2024, Rodman & Renshaw had reduced the stock from a Buy to Neutral. JMP Securities also reduced Mkt Perform rating. Additionally, BTIG Research reduced Neutral rating on September 4, 2024. Rodman & Renshaw analysts, in their report published on August 19, 2024, also initiated Buy rating and set a price target of $22 for Athira Pharma Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Athira Pharma Inc (ATHA) Stock Trading Recap
On Tuesday, Athira Pharma Inc (ATHA) stock saw a modest uptick, ending the day at $0.53 which represents a slight increase of $0.07 or 15.22% from the prior close of $0.46. The stock opened at $0.46 and touched a low of $0.46 during the day, reaching a high of $0.57. The volume of shares traded was 2.07 million exceeding the average volume of 0.78 million.
Sponsored
ATHA Stock Performance and Moving Averages
In recent trading, Athira Pharma Inc (ATHA) stock price has shown some volatility, fluctuating 19.04% over the last five trades and 25.95% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -74.07%, and it has plunged by -83.97% in the previous three months. Currently, ATHA is trading at 19.56%, -58.28%, and -78.29% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, ATHA, a Healthcare sector stock, is trading -87.69% below its 52-week high but remains 28.55% above its 52-week low. The Average True Range (ATR) (14 days) of 0.06 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Athira Pharma Inc’s Profitability and Valuation Ratios
Athira Pharma Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -74.07%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Athira Pharma Inc’s market capitalization stands at $20.33 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 0.24, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 7.89% of Athira Pharma Inc (ATHA)’s shares, while financial institutions hold 57.36%.
